Latest Breaking News On - வடக்கு நட்சத்திரம் ஆம்புலேட்டரி மதிப்பீடு - Page 1 : comparemela.com
F Hoffmann-La Roche Ltd: Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Babies with SMA able to swallow with Evrysdi® treatment
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Solid Biosciences Reports 1 5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, everyone, and welcome to Pfizer s second-quarter 2021 earnings conference call. Today s call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investment relations officer.
Please go ahead, sir.
Senior Vice President and Chief Investment Relations Officer
Thank you, Sylvia. Good morning. It s my pleasure to be welcoming you to Pfizer s second-quarter earnings call for the first time as the head of investor relations at Pfizer. I m joined today by Dr.
Albert Bourla, our chairman and CEO; Frank D Amelio, our CFO; Mikael Dolsten, president of worldwide research and development and medical; Angela Hwang, group president, Pfizer Biopharmaceuticals Group; John Young, our chief business officer; and Doug Lankler, general counsel. We ll begin the call with remarks by Albert, followed by a pipeline update from Mikael, and Frank will then give you his thoughts on the numbers and our updated guidance b